This Article Full Text Full Text (PDF) All Versions of this Article: bjo.2006.099598v1 90/11/1344    most recent Submit a response Read responses to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fung, A E Articles by Reichel, E Search for Related Content PubMed PubMed Citation Articles by Fung, A E Articles by Reichel, E Topic Collections Related Article

The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide

¹ Pacific Eye Associates, San Francisco, California, USA
² Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, Florida, USA
³ Department of Ophthalmology, New England Eye Center, Tufts University Medical Center, Boston, Massachusetts, USA

Correspondence to:
Correspondence to:
A E Fung
Pacific Eye Associates, 2100 Webster Street, Suite 214, San Francisco, CA 94115, USA;annefungmd{at}yahoo.com

ABSTRACT
Aim: Off-label intravitreal injections of bevacizumab (Avastin) have been given for the treatment of neovascular and exudative ocular diseases since May 2005. Since then, the use of intravitreal bevacizumab has spread worldwide, but the drug-related adverse events associated with its use have been reported only in a few retrospective reviews. The International Intravitreal Bevacizumab Safety Survey was initiated to gather timely information regarding adverse events from doctors around the world via the internet.

Methods: An internet-based survey was designed to identify adverse events associated with intravitreal bevacizumab treatment. The survey web address was disseminated to the international vitreoretinal community via email. Rates of adverse events were calculated from participant responses.

Results: 70 centres from 12 countries reported on 7113 injections given to 5228 patients. Doctor-reported adverse events included corneal abrasion, lens injury, endophthalmitis, retinal detachment, inflammation or uveitis, cataract progression, acute vision loss, central retinal artery occlusion, subretinal haemorrhage, retinal pigment epithelium tears, blood pressure elevation, transient ischaemic attack, cerebrovascular accident and death. None of the adverse event rates exceeded 0.21%.

Conclusion: Intravitreal bevacizumab is being used globally for ocular diseases. Self-reporting of adverse events after intravitreal bevacizumab injections did not show an increased rate of potential drug-related ocular or systemic events. These short-term results suggest that intravitreal bevacizumab seems to be safe.

Abbreviations: AMD, age-related macular degeneration; CVA, cerebrovascular accident; DVT, deep venous thrombosis; TIA, transient ischaemic attack

Related Article

BJO at a glance

Creig Hoyt
Br. J. Ophthalmol. 2006 90: 1333. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				R. D. Jager, W. F. Mieler, and J. W. Miller Age-Related Macular Degeneration N. Engl. J. Med., June 12, 2008; 358(24): 2606 - 2617. [Full Text] [PDF]

				K Kriechbaum, S Michels, F Prager, M Georgopoulos, M Funk, W Geitzenauer, and U Schmidt-Erfurth Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study Br. J. Ophthalmol., April 1, 2008; 92(4): 518 - 522. [Abstract] [Full Text] [PDF]

				S J McGimpsey and M C Gillies Treatment of macular degeneration - controversy and hope Br. J. Ophthalmol., March 1, 2008; 92(3): 436 - 437. [Full Text] [PDF]

				T C Kreutzer, C S Alge, A H Wolf, D Kook, J Burger, R Strauss, C Kunze, C Haritoglou, A Kampik, and S Priglinger Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion Br. J. Ophthalmol., March 1, 2008; 92(3): 351 - 355. [Abstract] [Full Text] [PDF]

				S V Goverdhan and J Lochhead Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration Br. J. Ophthalmol., February 1, 2008; 92(2): 210 - 212. [Abstract] [Full Text] [PDF]

				Z. F. Bashshur, A. Schakal, R. N. Hamam, C. P. El Haibi, R. F. Jaafar, and B. N. Noureddin Intravitreal Bevacizumab vs Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration Arch Ophthalmol, October 1, 2007; 125(10): 1357 - 1361. [Abstract] [Full Text] [PDF]

				A view on new drugs for macular degeneration DTB, July 1, 2007; 45(7): 49 - 52. [Full Text] [PDF]

				C. H. Meyer, J. Callizo, S. Mennel, and A. Kussin Perioperative Management of Anticoagulated Patients Undergoing Repeated Intravitreal Injections Arch Ophthalmol, July 1, 2007; 125(7): 994 - 994. [Full Text] [PDF]

				R. P A Manzano, G. A Peyman, P. Khan, P. E Carvounis, M. Kivilcim, M. Ren, J. C Lake, and P. Chevez-Barrios Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin) Br. J. Ophthalmol., June 1, 2007; 91(6): 804 - 807. [Abstract] [Full Text] [PDF]

				S K Gibran, A Sachdev, T Stappler, R Newsome, D Wong, and P Hiscott Histological findings of a choroidal neovascular membrane removed at the time of macular translocation in a patient previously treated with intravitreal bevacizumab treatment (Avastin) Br. J. Ophthalmol., May 1, 2007; 91(5): 602 - 604. [Abstract] [Full Text] [PDF]

				S. S Lynch and C. M Cheng Bevacizumab for Neovascular Ocular Diseases Ann. Pharmacother., April 1, 2007; 41(4): 614 - 625. [Abstract] [Full Text] [PDF]

				R B Bhisitkul Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br. J. Ophthalmol., December 1, 2006; 90(12): 1542 - 1547. [Abstract] [Full Text] [PDF]

eLetters: